BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA

Reuters01-08

Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O:

MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAY
MOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALS
MOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026

Source text: ID:nGNX5r5G75

Further company coverage: MLTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601626353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601626353","market":"fut","top_or_hot":-1,"title":"BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA </title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> <span>MLTX.O</span>:</p><ul><li><p>MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAY</p></li><li><p>MOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALS</p></li><li><p>MOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5r5G75</span></p><p>Further company coverage: <span>MLTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA </title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> <span>MLTX.O</span>:</p><ul><li><p>MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAY</p></li><li><p>MOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALS</p></li><li><p>MOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5r5G75</span></p><p>Further company coverage: <span>MLTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7WL1QM:1","article_id":"2601626353","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601626353","pubTimestamp":1767878764,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O:MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"简介-Moonlake Immunotherapeutics宣布与美国FDA B型会议取得积极成果","themeId":"33791b051befbfd8525af904615f530c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"BRIEF-Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA Jan 8 (Reuters) - MoonLake Immunotherapeutics MLTX.O:MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM TYPE B MEETING WITH U.S. FDA AND ANNOUNCES INVESTOR DAYMOONLAKE IMMUNOTHERAPEUTICS - FDA CONFIRMS MOONLAKE CAN ESTABLISH SEE WITHOUT ADDITIONAL TRIALSMOONLAKE IMMUNOTHERAPEUTICS - PLANS BLA SUBMISSION FOR SLK IN HS IN H2 2026Source text: ID:nGNX5r5G75Further company coverage: MLTX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601626353","isCrawlerRequest":true}